fosfomycin disodium

Fosfomycin disodium is the disodium salt injectable formulation of **fosfomycin**, a broad-spectrum epoxide antibacterial developed for intravenous use, particularly in hospitalized patients with serious multidrug-resistant bacterial infections. It inhibits early bacterial cell-wall synthesis by irreversibly inactivating **UDP-N-acetylglucosamine enolpyruvyl transferase**, thereby blocking peptidoglycan biosynthesis. In the provided public sources, this exact entity appears as **ZTI-01** and later **CONTEPO**, initially developed by Zavante Therapeutics, acquired by Nabriva Therapeutics, and subsequently acquired by Meitheal Pharmaceuticals for North American rights. Clinical development highlighted complicated urinary tract infection including acute pyelonephritis, as well as perioperative urinary infection prophylaxis in kidney transplant recipients; the product text provided also identifies CONTEPO as indicated in adults for complicated urinary tract infections caused by susceptible *Escherichia coli* and *Klebsiella pneumoniae*.

Brand names

CONTEPO

Other names

disodium fosfomycinintravenous fosfomycin disodiumfosfomycin for injectionIV fosfomycin